as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹556.4
Change
-4.6 (-0.82%)
Open
₹556.0
Prev. Close
₹561.0
Day High
₹561.0
Day Low
₹549.1
Volume Analysis
Traded
272,032
Delivered
158,269
Delivery %
58.18%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (34.0%)
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹573.8 | ₹567.4 | ₹561.9 | ₹555.5 | ₹550.0 | ₹543.6 | ₹538.1 |
| Fibonacci | ₹567.4 | ₹562.85 | ₹560.05 | ₹555.5 | ₹550.95 | ₹548.15 | ₹543.6 |
| Camarilla | ₹559.67 | ₹558.58 | ₹557.49 | ₹555.5 | ₹555.31 | ₹554.22 | ₹553.13 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-58.36%
1 Week
-7.54%
1 Month
-56.19%
3 Months
-64.59%
6 Months
-51.76%
1 Year
-61.37%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹112.4
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
15.23%
Net margin 23.85% × asset turnover 0.57x × equity multiplier 1.12x
Company Overview
Sector
Healthcare
Market Cap
₹12,146 Cr
P/E (TTM)
42.6
ROE
12.9%
Book Value
₹99.2
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.
TopFund Analysis
Concord Biotech Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 60/100. The strongest factor is Financial Strength (100/100), while Valuation (19/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (34.0%). FII holding has been rising.
TopFund Score — Fundamentals Quality
60/100 — AverageData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 28.2%
- −The company has delivered a poor sales growth of 11.3% over past five years.
- −Company has high debtors of 159 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Concord Biotech allotted 10,46,16,204 bonus shares on November 4, 2026, in 1:1 ratio.
Transcript of Q2 - FY27 Earnings call held on October 28, 2026
Q2 and half-year FY27 earnings call recording hosted on company website.
Concord Biotech will attend a UBS non-deal roadshow in Singapore on 3-4 November 2026.
Press release - For the Second quarter and half year ended on September 30, 2026
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 262 | 241 | 319 | 216 | 310 | 244 | 430 | 204 | 247 | 278 | 326 | 257 | 309 |
| Expenses + | 147 | 135 | 187 | 135 | 176 | 146 | 241 | 143 | 159 | 179 | 208 | 175 | 205 |
| Operating Profit | 116 | 106 | 132 | 81 | 134 | 98 | 189 | 61 | 88 | 98 | 118 | 82 | 104 |
| OPM % | 44.0% | 44.0% | 41.0% | 38.0% | 43.0% | 40.0% | 44.0% | 30.0% | 36.0% | 35.0% | 36.0% | 32.0% | 34.0% |
| Other Income + | 8 | 11 | 11 | 12 | 10 | 17 | 9 | 15 | 16 | 7 | 15 | 14 | 10 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 | 19 | 20 | 18 | 18 |
| Profit before tax | 110 | 103 | 129 | 80 | 130 | 101 | 184 | 59 | 86 | 86 | 114 | 78 | 95 |
| Tax % | 26.0% | 25.0% | 26.0% | 25.0% | 27.0% | 25.0% | 24.0% | 25.0% | 26.0% | 26.0% | 22.0% | 26.0% | 27.0% |
| Net Profit + | 81 | 78 | 95 | 60 | 96 | 76 | 140 | 44 | 63 | 64 | 88 | 58 | 70 |
| EPS in Rs | 4 | 4 | 5 | 3 | 5 | 4 | 7 | 2 | 3 | 3 | 4 | 3 | 3 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 65 | 0 | 17 | 11 | 18 | 1 | 35 | -5 | -20 | 14 | -24 | 26 | 25 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 (S) | Mar 2016 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 239 | 276 | 340 | 436 | 512 | 616 | 713 | 853 | 1,017 | 1,200 | 1,055 | 1,170 |
| Expenses + | 133 | 145 | 212 | 256 | 308 | 289 | 443 | 509 | 585 | 694 | 687 | 768 |
| Operating Profit | 105 | 131 | 127 | 180 | 205 | 327 | 270 | 344 | 432 | 506 | 368 | 403 |
| OPM % | 44.0% | 48.0% | 37.0% | 41.0% | 40.0% | 53.0% | 38.0% | 40.0% | 42.0% | 42.0% | 35.0% | 34.0% |
| Other Income + | 11 | 8 | 36 | 17 | 32 | 14 | 23 | 37 | 37 | 44 | 52 | 46 |
| Interest | 1 | 0 | 1 | 1 | 1 | 1 | 6 | 5 | 3 | 1 | 1 | 0 |
| Depreciation | 10 | 10 | 18 | 19 | 21 | 28 | 50 | 54 | 54 | 54 | 74 | 75 |
| Profit before tax | 106 | 129 | 144 | 178 | 214 | 313 | 238 | 322 | 413 | 495 | 345 | 374 |
| Tax % | 34.0% | 33.0% | 30.0% | 33.0% | 21.0% | 25.0% | 26.0% | 25.0% | 25.0% | 25.0% | 25.0% | — |
| Net Profit + | 70 | 87 | 100 | 118 | 169 | 235 | 175 | 240 | 308 | 372 | 259 | 279 |
| EPS in Rs | 3 | 4 | 5 | 6 | 8 | 11 | 8 | 11 | 15 | 18 | 12 | 14 |
| Dividend Payout % | 22.0% | 25.0% | 0.0% | 21.0% | 22.0% | 0.0% | 3.0% | 30.0% | 30.0% | 25.0% | 30.0% | — |
| Sales growth | — | 16 | — | 28 | — | 20 | 16 | 20 | 19 | 18 | -12 | 4 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 (S) | Mar 2016 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 268 | 329 | 585 | 673 | 761 | 990 | 1,094 | 1,280 | 1,516 | 1,802 | 2,007 | 2,065 |
| Borrowings + | 35 | 36 | 22 | 9 | 52 | 86 | 62 | 32 | 10 | 3 | 2 | 2 |
| Other Liabilities + | 55 | 74 | 69 | 71 | 118 | 97 | 147 | 192 | 164 | 219 | 212 | 249 |
| Total Liabilities | 367 | 448 | 685 | 763 | 941 | 1,183 | 1,313 | 1,514 | 1,701 | 2,034 | 2,232 | 2,327 |
| Fixed Assets + | 104 | 110 | 189 | 230 | 240 | 546 | 573 | 593 | 575 | 795 | 789 | 771 |
| CWIP | 19 | 70 | 3 | 19 | 141 | 18 | 74 | 173 | 211 | 51 | 79 | 112 |
| Investments | 42 | 43 | 151 | 229 | 199 | 141 | 74 | 137 | 246 | 335 | 491 | 533 |
| Other Assets + | 202 | 225 | 343 | 285 | 361 | 477 | 592 | 611 | 668 | 854 | 873 | 911 |
| Total Assets | 367 | 448 | 685 | 763 | 941 | 1,183 | 1,313 | 1,514 | 1,701 | 2,034 | 2,232 | 2,327 |
| Equity Capital | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 (S) | Mar 2016 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | — | — | 79 | — | 155 | 167 | 207 | 246 | 265 | 245 | 267 |
| Cash from Investing Activity + | — | — | -42 | — | -114 | -195 | -112 | -158 | -155 | -160 | -143 |
| Cash from Financing Activity + | — | — | -37 | — | -43 | 31 | -100 | -85 | -99 | -99 | -113 |
| Net Cash Flow | — | — | 0 | — | -1 | 3 | -4 | 3 | 12 | -14 | 11 |
| Free Cash Flow | — | — | 79 | — | -1 | -38 | 52 | 101 | 180 | 134 | 172 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | — | — | 101 | — | 100 | 74 | 99 | 92 | 85 | 70 | 100 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Nov 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 41.03% | 38.46% | 37.95% | 37.93% | 37.41% | 37.94% | 38.32% | 38.75% | 38.9% | 39.04% | 37.68% | 37.58% |
| Promoters | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.09% | 44.09% |
| FII | 6.49% | 7.11% | 8.1% | 8.33% | 9.35% | 9.1% | 8.03% | 7.58% | 7.79% | 7.53% | 7.28% | 7.33% |
| DII | 8.41% | 10.35% | 9.89% | 9.65% | 9.16% | 8.85% | 9.55% | 9.58% | 9.22% | 9.37% | 10.95% | 11.02% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Concord Biotech Limited (this stock) | 12,146 | 42.6 | 5.86 | 12.9% |
| Metropolis Healthcare Ltd | 11,711 | 50.7 | 7.13 | 13.6% |
| Rainbow Childrens Med Ltd | 12,607 | 43.0 | 7.34 | 16.7% |
| Viyash Scientific Limited | 11,285 | 46.6 | 3.56 | 7.39% |
| Akums Drugs And Pharma L | 11,279 | 29.9 | 3.22 | 8.45% |
| Park Medi World Limited | 11,039 | 43.1 | 5.12 | 16.8% |
| Marksans Pharma Limited | 13,347 | 23.8 | 4.0 | 15.2% |
Which Mutual Funds Hold Concord Biotech Limited?
Frequently Asked Questions about Concord Biotech Limited
Concord Biotech Limited (CONCORDBIO) closed at ₹556.4 on NSE on 19 November 2026, down 4.6 (0.82%) from the previous close.
Concord Biotech Limited trades on the NSE (National Stock Exchange of India) under the symbol CONCORDBIO.
Concord Biotech Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 42.6.
Concord Biotech Limited has a dividend yield of 0.65%.
Concord Biotech Limited's 52-week high is ₹808.0 and its 52-week low is ₹494.0.
Concord Biotech Limited has a market capitalisation of ₹12,146 crore.
Concord Biotech Limited has a TopFund Quality Score of 60/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Concord Biotech Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.